Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden

BACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting...

Full description

Bibliographic Details
Main Authors: Sarah Jonsson, Eva Lundin, Fredrik Elgh, Ulrika Ottander, Annika Idahl
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319302992
id doaj-238636a82bcd4ee4968de363602f7c1d
record_format Article
spelling doaj-238636a82bcd4ee4968de363602f7c1d2020-11-25T02:12:22ZengElsevierTranslational Oncology1936-52332020-01-011318691Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern SwedenSarah Jonsson0Eva Lundin1Fredrik Elgh2Ulrika Ottander3Annika Idahl4Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, Sweden; Address all correspondence to: Sarah Jonsson, Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, Sweden.Department of Medical Biosciences, Pathology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Microbiology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, SwedenDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, 901 87, SwedenBACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. MATERIALS AND METHODS: In a prospective nested case–control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001). CONCLUSIONS: The findings of this prospective nested case–control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.http://www.sciencedirect.com/science/article/pii/S1936523319302992
collection DOAJ
language English
format Article
sources DOAJ
author Sarah Jonsson
Eva Lundin
Fredrik Elgh
Ulrika Ottander
Annika Idahl
spellingShingle Sarah Jonsson
Eva Lundin
Fredrik Elgh
Ulrika Ottander
Annika Idahl
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
Translational Oncology
author_facet Sarah Jonsson
Eva Lundin
Fredrik Elgh
Ulrika Ottander
Annika Idahl
author_sort Sarah Jonsson
title Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
title_short Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
title_full Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
title_fullStr Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
title_full_unstemmed Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden
title_sort chlamydia trachomatis and anti-muc1 serology and subsequent risk of high-grade serous ovarian cancer: a population-based case–control study in northern sweden
publisher Elsevier
series Translational Oncology
issn 1936-5233
publishDate 2020-01-01
description BACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. MATERIALS AND METHODS: In a prospective nested case–control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001). CONCLUSIONS: The findings of this prospective nested case–control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.
url http://www.sciencedirect.com/science/article/pii/S1936523319302992
work_keys_str_mv AT sarahjonsson chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden
AT evalundin chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden
AT fredrikelgh chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden
AT ulrikaottander chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden
AT annikaidahl chlamydiatrachomatisandantimuc1serologyandsubsequentriskofhighgradeserousovariancancerapopulationbasedcasecontrolstudyinnorthernsweden
_version_ 1724909765598904320